Busulfex

(busulfan)

ApprovedSmall molecule

Busulfan is used to treat certain blood cancers, particularly chronic myeloid leukemia, and is also used to prepare patients for bone marrow or stem cell transplants by destroying cancer cells and suppressing the immune system.[2] Busulfex is currently approved and in use across 72 indications[4].[1]

Busulfex is one of 753 small molecule programs targeting Myelofibrosis. It is currently in Approved.

Indications

453

Total Trials

Active Trials

752

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

MyelofibrosisCompleted

TransplantationRecruiting

Acute Myeloid LeukemiaUnknown status

Wiskott-Aldrich SyndromeApproved

Niemann-Pick DiseaseApproved

Krabbe DiseaseApproved

HIV InfectionApproved

Non-Hodgkins LymphomaApproved

Wolman DiseaseApproved

AdrenoleukodystrophyApproved

MyelofibrosisPhase 2

Completed

TransplantationPhase 2

Recruiting

Acute Myeloid LeukemiaPhase 3

Unknown status

Wiskott-Aldrich SyndromeApproved

Approved

Niemann-Pick DiseaseApproved

Approved

Krabbe DiseaseApproved

Approved

HIV InfectionApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Wolman DiseaseApproved

Approved

AdrenoleukodystrophyApproved

Approved

Showing 10 of 72 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Approved

28 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Q1 2027

Phase 1Active, not recruiting

Maintenance Therapy

NCT03613532

Q4 2027

Phase 2Recruiting

Lymphoma

NCT02859402

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT03247088

Q3 2028

Phase 2Recruiting

Transplantation

NCT06252870

Clinical

Trials by Indication[1]

Stem Cell Transplant18 trials

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Completed·NNorthside Hospital, Inc.·Phase 2·NCT00782379·20 enrolled

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Withdrawn·NNorthside Hospital, Inc.·Phase 2·NCT06337331

Show 15 more trials

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Terminated·—·Phase 1/2·NCT00579111·4 enrolled

Allogeneic Stem Cell Transplant for CLL

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01629511·15 enrolled

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Completed·IInstitut Paoli-Calmettes·Phase 2·NCT00806767·82 enrolled

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Completed·UUniversity of California, Davis·Phase 2·NCT00619645·8 enrolled

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Completed·—·Phase 1·NCT00638898·25 enrolled

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Withdrawn·UUniversity of California, San Francisco·Phase 2·NCT00301912

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No longer available·BBarbara Ann Karmanos Cancer Institute··NCT00423826

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04776850

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting·DDiane George·Phase 1/2·NCT02061800·14 enrolled

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00857389·60 enrolled

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00346359·40 enrolled

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01056614·23 enrolled

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT00818961·36 enrolled

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Unknown status·IInstitut Paoli-Calmettes·Phase 2·NCT00740467·50 enrolled

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00245037·147 enrolled

Bone Marrow Transplantation17 trials

Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003195

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002502

Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00002554·30 enrolled

Show 14 more trials

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled

Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNorthwestern University·Phase 2·NCT00004896

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00014469

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

Completed·—·N/A·NCT00005893

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005641

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNorthwestern University·Phase 2·NCT00004899

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1·NCT00003060·6 enrolled

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003960·36 enrolled

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003101·60 enrolled

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Terminated·—·N/A·NCT00006054

Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation

Terminated·UUniversity of Illinois at Chicago·Phase 2·NCT01749293·3 enrolled

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Completed·EEuropean Infant Neuroblastoma Study Group - 1999·Phase 2·NCT00025649

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00705120·9 enrolled

Lymphoma11 trials

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Recruiting·KKeimyung University Dongsan Medical Center·Phase 2·NCT02859402·34 enrolled

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00238433·37 enrolled

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT02701673

Show 8 more trials

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 3·NCT00003414·50 enrolled

Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00005824

Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004171

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1/2·NCT00004907

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT04690192·30 enrolled

BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma

Unknown status·PPusan National University Hospital·Phase 2·NCT02836639·20 enrolled

Acute Myeloid Leukemia9 trials

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Completed·CChildren's Oncology Group·Phase 2·NCT00070174·350 enrolled

Show 6 more trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002768·51 enrolled

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00006363·720 enrolled

Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00004128·2,000 enrolled

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00416598·546 enrolled

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Completed·—·Phase 2·NCT01020734·263 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02441803·11 enrolled

Chronic Myelogenous Leukemia9 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027924

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Completed·—·Phase 2·NCT00002592·40 enrolled

Autologous Transplantation for Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01003054·24 enrolled

Show 6 more trials

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00305708·40 enrolled

Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005948

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Withdrawn·—·Phase 1/2·NCT00002761

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005986

Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia

Completed·NNorthwestern University·Phase 2·NCT00004181

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00813124·24 enrolled

68 more indications

Multiple Myeloma8 trials

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT00941720·71 enrolled

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02506959·83 enrolled

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00313625·20 enrolled

Show 5 more trials

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Completed·IInstitut Paoli-Calmettes·Phase 2·NCT00802568·48 enrolled

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

Terminated·UUniversity of Arkansas·Phase 1/2·NCT00113919·14 enrolled

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003146

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01758328·29 enrolled

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Terminated·UUniversity of Utah·Phase 2·NCT03303950·6 enrolled

Hematologic Malignancies7 trials

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01118013·6 enrolled

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02120157·35 enrolled

Show 4 more trials

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Terminated·UUniversity of Virginia·Phase 2·NCT01622556·6 enrolled

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Withdrawn·OOssium Health, Inc.·Phase 1·NCT05170828

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01760655·62 enrolled

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·—·Phase 2·NCT01093586·14 enrolled

Leukemia7 trials

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Completed·—·Phase 1·NCT01020539·18 enrolled

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Unknown status·—·Phase 1/2·NCT00679536·30 enrolled

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Show 4 more trials

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002549·1,520 enrolled

Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00667927·17 enrolled

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

Completed·UUniversity of Miami·N/A·NCT02007863·2 enrolled

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00623935·56 enrolled

Bone Marrow Transplant7 trials

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134017·142 enrolled

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005797·125 enrolled

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Terminated·OOHSU Knight Cancer Institute·N/A·NCT00253552·4 enrolled

Show 4 more trials

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00796562·107 enrolled

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04872595·59 enrolled

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Terminated·—·Phase 2·NCT00040469·15 enrolled

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Active, not recruiting·—·Phase 2·NCT00534430·30 enrolled

Conditioning7 trials

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Completed·Mmedac GmbH·Phase 3·NCT00822393·570 enrolled

Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.

Unknown status·SSeoul National University Hospital·Phase 2·NCT02047578·38 enrolled

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03229616·122 enrolled

Show 4 more trials

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02671708·153 enrolled

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03385096·122 enrolled

The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA

Unknown status·PPeking University People's Hospital·Phase 4·NCT06069180·160 enrolled

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT05453552·242 enrolled

Myelodysplastic Syndrome7 trials

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00077116·31 enrolled

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01168219·68 enrolled

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Completed·SSWOG Cancer Research Network·Phase 3·NCT00005866·240 enrolled

Show 4 more trials

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002989·207 enrolled

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·N/A·NCT00445744·52 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00024050

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Completed·—·Phase 1/2·NCT00003619

Hematopoietic Stem Cell Transplantation5 trials

Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML

Unknown status·SSeoul National University Hospital·Phase 2·NCT01274195·27 enrolled

Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic Modeling

Completed·SSeoul National University Hospital·Phase 1·NCT01018446·30 enrolled

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT04547049·176 enrolled

Show 2 more trials

Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H

Completed·TTehran University of Medical Sciences·Phase 1·NCT00458250·10 enrolled

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Terminated·MMalika Kapadia·Phase 1·NCT05569512·1 enrolled

Acute Leukemia5 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008190

Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00245115·7 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002831·24 enrolled

Show 2 more trials

Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT02605460·20 enrolled

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Unknown status·DDutch Childhood Oncology Group·N/A·NCT00550992·445 enrolled

Fanconi Anemia4 trials

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00258427·14 enrolled

Hematopoietic Stem Cell Transplant for Fanconi Anemia

Completed·MMedical College of Wisconsin·Phase 2·NCT01071239·1 enrolled

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Recruiting·—·Phase 2·NCT02143830·70 enrolled

Show 1 more trial

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03600909·3 enrolled

Neuroblastoma4 trials

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Unknown status·UUniversity of Leicester·Phase 3·NCT00030719·175 enrolled

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Terminated·—·Phase 1·NCT00670410·15 enrolled

Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 2·NCT00024193

Show 1 more trial

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00417053

Hematologic Cancer3 trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT00290628·43 enrolled

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Completed·—·Phase 2·NCT00003335·44 enrolled

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003661·3 enrolled

Transplantation3 trials

Study of Gelonin Purging of Autologous Stem Cells for Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00043810·3 enrolled

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Recruiting·NNantes University Hospital·Phase 2·NCT06252870·82 enrolled

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01572662·201 enrolled

Stem Cell Transplantation3 trials

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04370795

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Unknown status·MMilton S. Hershey Medical Center·Phase 2·NCT00084695·25 enrolled

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·—·Phase 2·NCT00003116·66 enrolled

Acute Lymphoblastic Leukemia3 trials

Busulfan and Cyclophosphamide Followed By ALLO BMT

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01685411·5 enrolled

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Unknown status·JJonsson Comprehensive Cancer Center·N/A·NCT00093587

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00002961·43 enrolled

Graft Versus Host Disease3 trials

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Withdrawn·MMesoblast International Sàrl·Phase 2·NCT00081055

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04127721

Trial2 trials

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Terminated·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT02627573·32 enrolled

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00506857·82 enrolled

Gene Therapy2 trials

Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency

Completed·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1/2·NCT01380990·36 enrolled

Autologous Gene Therapy for Artemis-Deficient SCID

Recruiting·UUniversity of California, San Francisco·Phase 1/2·NCT03538899·24 enrolled

Severe Combined Immunodeficiency2 trials

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Suspended·SSt. Jude Children's Research Hospital·Phase 1/2·NCT01512888·28 enrolled

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Unknown status·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03315078·13 enrolled

Toxicity2 trials

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05293509

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Chronic Granulomatous Disease2 trials

Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)

Unknown status·SSeoul National University Hospital·Phase 1/2·NCT01338675·5 enrolled

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02282904·7 enrolled

Myeloproliferative Disorder2 trials

Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00002792·20 enrolled

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00049634·30 enrolled

Breast Cancer2 trials

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003199·50 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00003972·280 enrolled

CNS Tumors1 trial

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01505569·44 enrolled

Tic Disorder1 trial

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Unknown status·—·N/A·NCT00006056·40 enrolled

MDS/AML1 trial

GVAX vs. Placebo for MDS/AML After Allo HSCT

Terminated·—·Phase 2·NCT01773395·123 enrolled

Histiocytosis1 trial

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00334672·288 enrolled

Stem Cells1 trial

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

Completed·UUniversity of California, Los Angeles·Phase 1/2·NCT01852071·46 enrolled

Ewing sarcoma1 trial

A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

Withdrawn·UUniversity of Louisville·Phase 1·NCT01969942

Peripheral Blood Stem Cell Transplantation1 trial

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01427881·43 enrolled

TED1 trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07441967·44 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Myeloid1 trial

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

Completed·—·Phase 1·NCT02916979·20 enrolled

Refractory Solid Tumors1 trial

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed·MMilton S. Hershey Medical Center·Phase 1·NCT00112645·10 enrolled

Acute Promyelocytic Leukemia1 trial

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled

Intensity-modulated Radiation Therapy1 trial

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Terminated·—·Phase 1/2·NCT00540995·25 enrolled

Myelofibrosis1 trial

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006367

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

Thalassemia1 trial

Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00029380·30 enrolled

Osteopetrosis1 trial

Allogeneic Transplantation For Severe Osteopetrosis

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00775931·7 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00448357·54 enrolled

Malignant Solid Tumors1 trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00436761·20 enrolled

Solid Tumors1 trial

MT2004-30: Tomotherapy for Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00623077·23 enrolled

Donor1 trial

URMC Related Haplo-identical Donor BMT

Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled

Pilot Study1 trial

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Completed·—·Phase 2·NCT00003336·6 enrolled

Recurrent or Metastatic1 trial

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Completed·—·N/A·NCT00521430·30 enrolled

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Glioma1 trial

Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas

Completed·—·N/A·NCT00253487

Sickle Cell Disease1 trial

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Active, not recruiting·—·Phase 2·NCT00408447·53 enrolled

Aplastic Anemia1 trial

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Unknown status·UUniversity of California, San Francisco·N/A·NCT00295997·35 enrolled

Myelodysplastic Syndromes1 trial

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Hematological Diseases1 trial

Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

Completed·WWake Forest University Health Sciences·Phase 2·NCT02248597·27 enrolled

HIV-1 infection1 trial

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Completed·CCalimmune, Inc.·Phase 1/2·NCT01734850·13 enrolled

Hematologic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003913·390 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Kidney Cancer1 trial

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Withdrawn·NNorthwestern University·Phase 1·NCT00006126

Myeloid Leukemia1 trial

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00002789·100 enrolled

Hematologic Malignancy1 trial

Terminated·—·Phase 2·NCT01500161·1 enrolled

Primitive Neuroectodermal Tumor1 trial

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00003081·16 enrolled

Mantle Cell Lymphoma1 trial

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004231

Children1 trial

Target Busulfan Exposure in Children With HSCT in China

Unknown status·TThe First Affiliated Hospital of Soochow University··NCT04786002·500 enrolled

Acute Graft Versus Host Disease1 trial

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT01044745·20 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Withdrawn·NNationwide Children's Hospital·Phase 2·NCT00874315

Efficacy and Safety1 trial

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Completed·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1/2·NCT03765632·13 enrolled

Maintenance Therapy1 trial

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Active, not recruiting·JJacqueline Garcia, MD·Phase 1·NCT03613532·102 enrolled

Tocilizumab1 trial

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

Prevention1 trial

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03018223·32 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT01824693·30 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

MYLERAN

NDA NDA009386

Feb 4, 1999

BUSULFEX

NDA NDA020954

Sources

References

[1]
ClinicalTrials.gov — 453 trial records for busulfan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Busulfex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — busulfan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for busulfan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020954). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Akero Therapeutics